Metabolic Diseases Clinical Trial
— 3GOfficial title:
Gut, Grain and Greens (3G): The Effect of Gluten on Gut Microbiome and Metabolic Health.
Verified date | December 2013 |
Source | University of Copenhagen |
Contact | n/a |
Is FDA regulated | No |
Health authority | Denmark: Danish Dataprotection Agency |
Study type | Interventional |
Objective: To identify how specific changes of the gluten content in the diet affect the
host-gut microbiome interactions with implications for metabolic health.
Design: A randomized, controlled, single-blinded, cross-over intervention trial consisting
of two 8-week interventions periods, separated by a 6-week wash-out period. A total number
of 60 participants will be included.
Intervention: low vs high gluten intake.
Status | Completed |
Enrollment | 60 |
Est. completion date | November 2013 |
Est. primary completion date | November 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria, compulsory: - Body mass index (BMI): 25 - 35 kg/m2 OR - Abdominal obesity: waist circumference: men: = 94cm; women: = 80cm - No medically prescribed diet - Weight stable - Intense sporting activities less than 10 h/week - Alcohol consumption less than 14 units/week (female) and 21 units/week (male) - Signed informed consent Inclusion criteria, minimum one of the following: - Fasting plasma glucose from 6.1 mmol/l to 6.9 mmol/l - Reduced high density lipoprotein (HDL) cholesterol; HDL = 1.03 mmol/L for men and = 1.29 mmol/L for women - Increased triglyceride (TG) > 1.3 mmol/L - Systolic blood pressure > 130 mmHg Exclusion Criteria: - Pharmacological treatment; diabetes and blood lipid regulation - Lactating (or lactating, 6 weeks ago), pregnant (or pregnant, 3 months ago) or wish to become pregnant during the study - Participation in another biomedical trial 1 month prior to study start - Diagnosed with any form of diabetes, celiac disease or chronic pancreatitis - Reported chronic gastrointestinal disorders - Antibiotic treatment for 3 month prior to study start - Blood hemoglobin < 7.0 mmol/l - Blood donation within 1 month prior to study start |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
Denmark | The Novo Nordisk Foundation of Basic Metabolic Health, Section for Metabolic Genetics | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
University of Copenhagen | Technical University of Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | 4 days precoded food diary. | Validated method for dietary registration, based on 2 week and 2 weekend days. | Up to 2 years. | No |
Other | Gastrointestinal symptoms. | Changes from baseline to after intervention in individual gastrointestinal symptoms by validated VAS-questionary. | Up to 2 years. | No |
Primary | Altered quantitative metagenomics at bacterial gene- and species levels. | Feces samples are collected according to standard operation procedures for subsequent standardized microbial DNA extraction. Microbial DNA will be subjected to sequencing, microbial gene analyses, taxonomy analyses including enterotypes known species and unknown meta-species and functional annotation. | Up to 3 years. | No |
Secondary | Mean intestinal transit time | Participants are instructed in swallowing capsules containing different small non-invasive and non-absorbable plastic pellets for 6 consecutive days. On the seventh day they are having an X-ray of the abdomen taken. | Up to 2 years. | No |
Secondary | Gastrointestinal permeability. | Lactulose/mannitol ratio in urine after four hours collection following oral intake of lactulose and mannitol. | Up to 2 years. | No |
Secondary | Colonic fermentation | Breath hydrogen after intake of standardized breakfast (30,60,90,120,180 minutes) | Up to 2 years. | No |
Secondary | Blood pressure and pulse. | Systolic and diastolic blood pressure and heart beat rate are measured after 10 min of rest according to current standard operational procedure with an automatic blood pressure meter. Participants are instructed not to talk during the measurements. | Up to 1 year. | No |
Secondary | Saliva microbial flora | Saliva is collected after the participants have taken a small piece of paraffin in their mouth and have chewed until the paraffin has turned into one coherent mass (approximately one minute). Participants are swallowing the produced saliva for that minute. After this, and for the next 3 minutes, saliva is collected in a cup and handed over to the study personnel. Saliva is stored at minus 80 degrees for later studies of saliva microbial flora and saliva biochemistry. | Up to 2 years. | No |
Secondary | Nasal fluid | Nasal fluid is collected by a non-invasive methodology for in vivo measurement of an array of immunological signalling molecules in the nasal airway lining. The method is based on a standardized collection of mucosal airway fluid from both nostrils onto small sheets of filter papers with efficient absorption properties. The technique is highly reproducible, and used for measuring immunological mediators representing the immediate response ability of the mucosal immune system. | Up to 3 years. | No |
Secondary | Appetite hormones | Glucagon like peptide 1 and 2, Gastric inhibitory polypeptide, peptide YY and Ghrelin. | Up to 3 years. | No |
Secondary | Celiac disease markers | Levels of gliadin and Immunoglobulin A and G transglutaminase. | Up to 1 year. | No |
Secondary | Blood lipid profile | Low density Lipoproteins, High density lipoproteins, Total Cholesterol, Very low density lipoproteins and Free fatty acids. | Up to 2 years. | No |
Secondary | Bioimpedance | Body composition (lean body mass and fat mass) is measured by bio-electrical impedance using multi frequency Quadscan. | Up to 1 year. | No |
Secondary | Breath hydrogen. | Breath hydrogen measurements are done before the intake of the standardized breakfast (at 30, 60, 90, 120, 180 minutes), as an indicator of colonic fermentation. | Up to 2 years. | No |
Secondary | Insulin | Fasting insulin and post prandial at 30, 60, 90, 120 and 180 minutes after standardized meal. | Up to 2 years. | No |
Secondary | Glucose | Fasting glucose and post prandial at 30, 60, 90, 120 and 180 minutes after standardized meal. | Up to 2 years. | No |
Secondary | C-peptide | Fasting. | Up to 2 years. | No |
Secondary | Inflammatory makers | High sensitive C-reactive protein, Interleukin 1, 6 and 10, Lipopolysaccharide- binding protein, Tumor necrosis factor - alfa. | Up to 3 years. | No |
Secondary | Anthropometric characteristics. | Weight, height, sagittal height and waist circumference. | Up to 1 year. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02402985 -
Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics
|
N/A | |
Not yet recruiting |
NCT01916603 -
Diet, Physical Activity and Breastfeeding Intervention on Maternal Nutrition, Offspring Growth and Development
|
N/A | |
Completed |
NCT02380846 -
The Metabolic Effects of Consuming Carbohydrate With Different Protein Types
|
N/A | |
Completed |
NCT01616082 -
Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)
|
N/A | |
Completed |
NCT01737164 -
Effect of Age on Glucose and Lipid Metabolism
|
N/A | |
Terminated |
NCT00935766 -
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
|
Phase 3 | |
Enrolling by invitation |
NCT00628199 -
Study to Create Potential Cell-Based Therapies to Treat Human Disease and Disability
|
||
Recruiting |
NCT04958109 -
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
|
Phase 1 | |
Completed |
NCT02275429 -
Metabolic Disorders in Ultramarathon Runners During and After the Reunion Island Madmen's Diagonal
|
N/A | |
Completed |
NCT01968720 -
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
|
Phase 2 | |
Completed |
NCT01708681 -
Lean Seafood Intake and Postprandial Metabolism
|
N/A | |
Completed |
NCT01705782 -
The Effects of Amino Acid Supplement During Acute Inflammation.
|
N/A | |
Completed |
NCT01435382 -
A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia
|
Phase 1 | |
Recruiting |
NCT02629926 -
Transitional Growth Hormone (GH) Use in Growth Hormone Deficient (GHD) Cancer Survivors
|
Phase 4 | |
Completed |
NCT00707746 -
Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
|
Phase 2 | |
Completed |
NCT00550706 -
Drug Utilization Prevalence in a Pediatric Care Medical Center
|
N/A | |
Completed |
NCT03941392 -
Nutritional Study in Spanish Pediatric Population
|
||
Terminated |
NCT02440945 -
Use of the DBS for the Follow-up of Blood Clinical Parameters of Old People
|
N/A | |
Not yet recruiting |
NCT06000605 -
Brain Substrate Switch to Ketones and Lactate
|
N/A | |
Recruiting |
NCT05236374 -
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc
|
N/A |